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Abstract  
 
Metaflammation in adipose tissue, which is characterized by increased local gene expression and 
secretion of pro-inflammatory factors, may contribute to the increased risk of metabolic 
complications in obesity. It has been suggested that IL-1β might induce metaflammation in 
adipose tissue via modulating the NF-κB signaling pathway. In our study, the mRNA and secretion 
levels of major pro-inflammatory factors including IL (interleukin)-1β, IL-6, IL-8, MCP 
(monocyte chemoattractant protein)-1 and RANTES (regulated on activation, normal T cell 
expressed and secreted) were measured as indicators of the inflammatory profile. We herein 
showed that IL-1β could induce adipose tissue metaflammation by enhancing the inflammatory 
profile of preadipocytes. Moreover, IL-1β could enhance pro-inflammatory gene expression by 
increasing the phosphorylation or decreasing the methylation of relA (NF-κB p65) of the NF-κB 
signaling pathway. VDR (vitamin D receptor) ligands have been shown to have anti-inflammatory 
properties in adipocytes. Likewise, our study demonstrated that the inflammatory profile of 
IL-1β-stimulated preadipocytes is significantly attenuated by VDR ligands 1α,25(OH)2D3, 
ZK159222 and ZK191785. Importantly, we showed that ZK159222 and ZK191785 could inhibit 
pro-inflammatory gene expression by decreasing the phosphorylation or increasing the 
methylation of relA. Furthermore, pro-inflammatory secretion could be reduced by 1α,25(OH)2D3, 
ZK159222 and ZK191785 via increasing the phosphorylation of eIF (eukaryotic translation 
initiation factor)-2α of the UPR (unfolded protein response) pathway. These observations suggest 
that the VDR ligands may be considered potential anti-inflammatory treatments for obesity 
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associated metabolic complications. 
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1. Introduction 
 
Obesity has become a leading global public health problem as it is considered as a risk factor for a 
variety of metabolic diseases including type 2 diabetes, hepatic steatosis, biliary disease, 
neurodegeneration, cardiovascular diseases, musculoskeletal abnormalities and even some cancers 
[1]. The risk of developing these obesity-related complications is determined in part by the degree 
of metaflammation in adipose tissue [2], characterized by moderate local expression of a plethora 
of pro-inflammatory factors [3]. Besides being triggered by ER (endoplasmic reticulum) stress 
during adipose tissue expansion in obesity [4], accumulated research evidence also indicates that 
metaflammation could be induced by IL-1β via activating IKKβ and the down-stream 
transcription factor NF-κB in the classical receptor-mediated way [5,6,7]. It is worth noting that 
mice lacking the IL-1β-receptor show attenuated adipose tissue metaflammation in response to a 
high fat diet, which coincides with protection against insulin resistance [8]. Hence, the metabolic 
outcomes of obese individuals might be improved by attenuating IL-1β-enhanced inflammatory 
profile in adipose tissue.  
 
                                                   
Abbreviations: EGF, epidermal growth factor; eIF, eukaryotic translation initiation factor; ER, 
endoplasmic reticulum; G-CSF, granulocyte colony-stimulating factor; IL, interleukin; IP, 
interferon gamma-induced protein; MCP, monocyte chemoattractant protein; MIP, macrophage 
inflammatory protein; RANTES, regulated on activation, normal T cell expressed and secreted; 
UPR, unfolded protein response; VDR, vitamin D receptor.  
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Adipose tissue is the principal storage site of the fat soluble secosteroid vitamin D and its 
metabolites [9]. 1α,25(OH)2D3, acting as a VDR ligand, not only participates in bone and mineral 
metabolism, but also modulates cell proliferation, differentiation and immune-regulation 
[10,11,12]. Most intriguingly, recent studies reported that 1α,25(OH)2D3 could attenuate the 
inflammatory profile of human adipocytes [13,14]. However, the immuno-modulatory properties 
of 1α,25(OH)2D3 are mostly achieved at very high doses, that provoke hypercalcemia, which 
prevents its use as a practical clinical anti-inflammatory agent [15]. During recent decades, 
attempts have been made to synthesize other VDR ligands with anti-inflammatory efficacy but 
lower capacity to raise blood calcium levels [15]. 
 
In this study, we aimed to test whether 1α,25(OH)2D3, and two synthetic VDR ligands (ZK191784 
and ZK15922) could attenuate the inflammatory profile of IL-1β-stimulated human white 
preadipocytes by inhibiting the gene expression and secretion of major pro-inflammatory factors. 
This was determined by examining the modifying effects of the VDR ligands on signaling 
molecules relA of the NF-κB pathway and eIF-2α of the UPR pathway activated during ER stress.  
 
2. Materials and Methods 
 
2.1. Culture media and conditions of human white preadipocytes 
 
Human white preadipocytes derived from subcutaneous adipose tissue of a female Caucasian 
subject (BMI 21; age 44 years) were obtained from PromoCell (Germany). The preadipocytes 
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were cultured in T25 flasks then sub-cultured into 12-well plates (seeding density: 5000 cells per 
cm
2
) in preadipocyte growth medium (PromoCell, Germany) supplemented with 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B, and incubated at 37°C in 95% 
air and 5% CO2.  
 
2.2. IL-1β stimulation and VDR ligand pre-treatment and treatment  
 
VDR ligands ZK159222, ZK191784 (kindly provided by Bayer AG, Germany) and 1α,25(OH)2D3 
(ENZO Life Sciences, USA) (reconstituted in DMSO to a concentration of 1 μg/μl) were diluted 
to final concentrations (indicated as below) in preadipocyte growth medium. The purpose of VDR 
ligand pre-treatments was to boost the efficacy as established previously [16]. When confluence 
was reached, preadipocytes (n=6 wells per group) were pre-treated with ZK 159222 (10 nM and 1 
μM) or ZK191784 (10 nM and 1μM) or 1α,25(OH)2D3 (0.01-10 nM and 1 μM), or with 
preadipocyte growth medium alone as a control. After 48 h the pre-treatment media were 
discarded. Then, IL-1β (reconstituted in distilled water to a concentration of 0.1 μg/μl, R&D 
Systems, UK) was added 2 ml/well to induce metaflammation together with ZK159222, 
ZK191784 or 1α,25(OH)2D3 or control media at the same concentrations as used for the 
pre-treatment period and cultured for a further 24 h before cell and supernatant collection. 
 
2.3. Inflammatory profile measurement 
 
The mRNA levels of major pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and 
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RANTES of preadipocytes were measured in duplicate using TaqMan gene expression assays 
(Applied Biosystems, UK), qPCR core kit (Eurogentec, Belgium) and Stratagene Mx3005P 
instrument system. The results were normalized to the values of reference gene PPIA [17] and 
presented as fold changes of Ct value relative to controls using the 2
−ΔΔct
 formula [18]. The 
concentrations of IL-6, IL-8, MCP-1 and RANTES of the cell supernatants were measured in 
duplicate using human ELISA kits following the manufacturer’s instructions (R&D Systems, UK) 
and SPECTROstar Nano Microplate Reader (BMG LABTECH, Germany). The results were 
corrected for total cell protein content (measured by Thermo Scientific Pierce BCA Protein Assay 
Kit, UK) and presented μg(cytokine)/mg(cell protein). Cytokine secretion profile of the pooled 
cell supernatants (n=6) were determined by Proteome Profiler Human XL Cytokine Array 
following the manufacturer’s instructions (R&D Systems, UK) and Molecular Imager ChemiDoc 
XRS+ System (Bio-Rad, UK). The results were presented as pixel density relative to the 
references of the arrays. The intracellular levels (densities) of signaling molecules including relA, 
phosphorylated relA, methylated relA, eIF-2α phosphorylated eIF-2α were measured using 
western blotting and Molecular Imager ChemiDoc XRS+ System (Bio-Rad, UK). All the 
antibodies used were purchased from Abcam (UK) and diluted according to the manufacturer’s 
instructions. The results were calculated as ratios of phosphorylated relA to relA, methylated relA 
to relA and phosphorylated eIF-2α to eIF-2α, normalized to loading control vinculin, and 
presented as fold changes of density relative to controls. Methods of qPCR and western blotting 
were as previously described [16]. 
 
2.4. Statistical analysis  
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Results are presented as means ± SEM. For statistical analysis, one-way ANOVA test for 
independent samples was used, followed by Tukey’s test for individual group comparisons. A 
value of P<0.05 was regarded as statistically significant. The analysis and presentation were 
performed using Prism 5 (GraphPad, USA). 
 
3. Results  
 
3.1. VDR ligands affect the gene expression of major pro-inflammatory factors in 
IL-1β-stimulated human white preadipocytes  
  
IL-1β is critical in initiating and maintaining metaflammation in adipose tissue [8,19]. To 
investigate whether metaflammation induced by IL-1β might originate in preadipocytes – a critical 
component of adipose tissue [20], we treated human white preadipocytes with a moderate dose 
(0.5 ng/ml) of IL-1β. The qPCR results show that (Fig. 1) the mRNA levels of major 
pro-inflammatory factors including IL-1β, IL-6, IL-8, MCP-1 and RANTES were markedly 
increased, suggesting that IL-1β could target preadipocytes to propagate adipose tissue 
metaflammation.  
 
We speculated that 1α,25(OH)2D3 might inhibit pro-inflammatory gene expression in 
preadipocytes, as has previously been shown in human adipocytes [13,14]. In preliminary work, a 
range of doses from 0.01 to 10 nM of 1α,25(OH)2D3 were tested, and the reducing effects on the 
9 
 
mRNA levels of the major pro-inflammatory factors were consistent within this dose range (Fig. 
S1). (Fig. 1) The mRNA levels of IL-1β, IL-6, IL-8, MCP-1 and RANTES were moderately 
decreased by 10 nM of 1α,25(OH)2D3, which were ~0.7 to 1.9-fold lower compared with 
IL-1β-stimulated preadipocytes. Synthetic VDR ligands, ZK159222 and ZK191784 (10 nM) were 
also tested in the same protocol and (Fig. 1) the pro-inflammatory mRNA levels were reduced by 
~0.7 to 2.3 and ~1.5 to 1.8-fold, respectively. In parallel, considering the very high doses of VDR 
ligands applied clinically [15], a higher dose of 1 μM of 1α,25(OH)2D3 was also tested. This dose 
resulted in apoptosis of preadipocytes in 4 hours so was not tested further. In contrast, (Fig. 1) 1 
μM of ZK159222 decreased the mRNA levels of IL-6, IL-8, MCP-1 and RANTES by 
~0.5-1.6-fold but not IL-1β. Finally, (Fig. 1) 1 μM of ZK191784 reduced the major 
pro-inflammatory mRNA levels by ~1.4 to 2.9-fold. Taken together, these data show that all the 
VDR ligands tested attenuate the inflammatory profile of preadipocytes enhanced by IL-1β, by 
inhibiting pro-inflammatory gene expression. However, ZK159222 and ZK191784 might be 
pharmacologically less toxic than 1α,25(OH)2D3, for 1 μM of the latter induced apoptosis of 
preadipocytes. 
  
3.2. VDR ligands affect the secretion of major pro-inflammatory factors from IL-1β-stimulated 
human white preadipocytes  
 
Using ELISAs to measure concentrations of IL-6, IL-8, MCP-1 and RANTES in supernatants 
from cultured preadipocytes, (Fig. 2) the secretion levels of IL-6, IL-8, MCP-1 and RANTES were 
dramatically increased from IL-1β-stimulated preadipocytes, whereas the VDR ligands inhibited 
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the pro-inflammatory secretion. As observed in preliminary work, within the dose range the 
decreasing effects of 1α,25(OH)2D3 were consistent (Fig. S2). (Fig. 2) Compared with 
IL-1β-stimulated preadipocytes, 10 nM of 1α,25(OH)2D3, ZK159222 and ZK191784 decreased 
the secretion of the major pro-inflammatory factors by ~0.4 to 0.6-fold. In parallel, 1 μM of 
ZK159222 decreased the levels of IL-6, IL-8 and RANTES by ~0.4 to 0.5-fold, although 
concentrations of MCP-1 were numerically lower, this did not reach statistical significance. 1 μM 
of ZK191784 moderately reduced the levels of IL-6, IL-8 and MCP-1 by ~0.4 to 0.5-fold, but did 
not significantly affect RANTES. Therefore, the VDR ligands could also attenuate the 
inflammatory profile of preadipocytes by reducing secretion of pro-inflammatory factors. 
 
Next, (Fig. 3A) we performed proteome array to explore whether 1 μM of ZK159222 and 
ZK191784 could affect the secretion of other cytokines from IL-1β-stimulated preadipocytes. The 
result revealed that (Fig. 3B) besides IL-6, IL-8, MCP-1 and RANTES, ZK159222 and ZK191784 
reduced the levels of a variety of pro-inflammatory factors including EGF (epidermal growth 
factor), G-CSF (granulocyte colony-stimulating factor), GRO-a, IP (interferon gamma-induced 
protein)-10, MCP-3, MIP (macrophage inflammatory protein)-3a, pentraxin-3 and 
thrombospondin. 
 
3.3. VDR ligands modify inflammatory associated signaling molecules in IL-1β-stimulated 
human white preadipocytes  
 
The NF-κB signaling pathway could be activated by IL-1β via degrading I-κB to release NF-κB 
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p65/p50 heterodimer into the nucleus [7]. As a key transcription factor, post-translationally 
modified NF-κB regulates the expression of pro-inflammatory genes including IL-1β, IL-6 and 
MCP-1 [21]. As shown in Fig. 4A, the levels of relA were similar in control and IL-1β-stimulated 
preadipocytes, but (Fig. 4B) IL-1β significantly increased the phosphorylation level of relA by 
~85%. By contrast, (Fig. 4C) the methylation level was reduced by ~33%. IκBα was also 
measured, but no effect of IL-1β on its intracellular concentration was observed (data not shown). 
The overall results suggest that IL-1β could enhance pro-inflammatory gene expression by 
increasing the phosphorylation or decreasing the methylation of relA of the NF-κB signaling 
pathway in preadipocytes. 
 
In preliminary work, IκBα, relA, phosphorylated and methylated relA were probed to determine 
the modulating effects of 1α,25(OH)2D3 (0.01-10 nM) on the NF-κB pathway, but all the levels 
were comparable to IL-1β-stimulated preadipocytes (data not shown), which indicates that 
1α,25(OH)2D3 does not modulate the NF-κB pathway in IL-1β-stimulated preadipocytes. Likewise, 
10 nM and 1 μM of ZK159222 and ZK191784 had no effect on the levels of IκBα (data not shown) 
and (Fig. 4A) relA. However, (Fig. 4B) 1 μM of ZK159222 and ZK191784 decreased the 
phosphorylation levels of relA by ~34%. (Fig. 4C) In parallel, 10 nM and 1 μM of ZK159222 and 
10 nM of ZK191784 were associated with moderately (~44%) higher methylation levels of relA in 
IL-1β-stimulated preadipocytes. However, (Fig. 4B and C) 10 nM of ZK159222 and ZK191784 
and 1 μM of ZK191784 had no effect on the levels of phosphorylation and methylation of relA, 
respectively. Taken together, ZK159222 and ZK191784 could inhibit pro-inflammatory gene 
expression by decreasing the phosphorylation or increasing the methylation of relA in 
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IL-1β-stimulated preadipocytes. 
 
The UPR can relieve ER stress [22,23], which is one of the potential causes of metaflammation in 
adipose tissue [4]. As one of the vital signaling molecules of the UPR pathways, phosphorylated 
eIF-2α could halt the general translation by ubiquitylation [24]. Therefore, we speculated that the 
VDR ligands might reduce the secretion of the major pro-inflammatory factors by increasing the 
phosphorylation of eIF-2α. (Fig. 4A) The levels of eIF-2α and phosphorylated eIF-2α were similar 
in control and IL-1β-stimulated preadipocytes. 0.1 to 10 nM of 1α,25(OH)2D3 also had no effect 
on the levels of eIF-2α, but consistently increased the phosphorylation levels of eIF-2α by ~43% 
to ~73%, compared to IL-1β-stimulated preadipocytes (Fig. S3 and Fig. 4A and D). Likewise, (Fig. 
4A) 10 nM and 1 μM of ZK159222 and ZK191784 had no effect on the levels of eIF-2α, (Fig. 4D) 
but were associated with markedly (~47%) higher phosphorylation levels of eIF-2α. The overall 
results suggest by increasing the phosphorylation of eIF-2α of the UPR pathways, 1α,25(OH)2D3, 
ZK159222 and ZK191784 could reduce pro-inflammatory secretion from IL-1β-stimulated 
preadipocytes. 
 
4. Discussion 
 
IL-1β could induce adipose tissue metaflammation by modulating the NF-κB pathway [8,19]. Our 
study began with investigating whether metaflammation induced by IL-1β might originate in 
preadipocytes, by measuring the mRNA and secretion levels of major pro-inflammatory factors 
including IL-1β, IL-6, IL-8, MCP-1 and RANTES as indicators of the inflammatory profile in 
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keeping with published studies [25,26,27,28,29,30] . Our results indicate that the inflammatory 
profile of preadipocytes is significantly enhanced by IL-1β. Moreover, IL-1β could enhance 
pro-inflammatory gene expression via increasing the phosphorylation or decreasing the 
methylation of relA of the NF-κB signaling pathway, as previously suggested [31,32,33,34].  
 
The risk for obese individuals to develop metabolic complications might be reduced by 
attenuating IL-1β-enhanced inflammatory profiles in preadipocytes, because the homeostasis of 
obese adipose tissue is dependent on preadipocytes exerting beneficial effects, protecting against 
metabolic complications [20,35], but IL-1β could enhance the major pro-inflammatory gene 
expression of preadipocytes as demonstrated in our study, which might sabotage the metabolic 
signaling of adipose tissue e.g. by causing insulin resistance [36]. 
 
VDR ligands have been shown to exert anti-inflammatory properties in adipose tissue [16,37,38]. 
Likewise, 1α,25(OH)2D3, ZK159222 and ZK191784 attenuate pro-inflammatory gene expression 
and secretion enhanced by IL-1β in preadipocytes. Moreover, ZK159222 and ZK191784 exhibited 
a more extensive inhibitory effect on secretion of pro-inflammatory factors including EGF, G-CSF, 
GRO-a, IP-10, MCP-3, MIP-3a, pentraxin-3 and thrombospondin. Besides VDR ligands directly 
regulate the gene expression of cytokines [39], by decreasing the phosphorylation or increasing 
the methylation of relA, ZK15922 and ZK191784 could inhibit pro-inflammatory gene expression, 
as formerly established [37,38]. Importantly, 1α,25(OH)2D3, ZK159222 and ZK191784 could also 
reduce pro-inflammatory secretion via increasing the phosphorylation of eIF-2α of the UPR 
pathway, thereby abating the general translation to relieve metaflammation triggered by ER stress 
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[4,22,23,24]. The potential mechanism might be the VDR ligands triggering Ca
2+
 release from ER 
stores [40]. 
 
In summary, we have demonstrated that IL-1β enhances the inflammatory profile of human 
preadipocytes by post-translationally modifying relA of the NF-κB pathway. Furthermore, we 
have shown that the VDR ligands inhibit the inflammatory profile, and that the anti-inflammatory 
mechanisms could be due to a decrease in the phosphorylation or an increase in the methylation of 
relA by ZK159222 and ZK191785, and finally that 1α,25(OH)2D3, ZK159222 and ZK191785 also 
increase the phosphorylation of eIF-2α of the UPR pathway. Therefore, the VDR ligands tested 
may be considered potential anti-inflammatory treatments for obesity associated metabolic 
complications. 
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Fig. 1. Effects of VDR ligands on pro-inflammatory gene expression in IL-1β-stimulated 
human white preadipocytes. 
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) for 24 h. Further 
groups of cells were pre-treated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or 
ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a 
further 24 h before cell collection. The mRNA levels of pro-inflammatory factors (A) IL-1β, (B) 
IL-6, (C) IL-8, (D) MCP-1 and (E) RANTES were measured by qPCR. Data are means ± SEM for 
groups of 6. A significant difference to control was indicated by ***(p<0.001); to IL-1β by 
#(p<0.05), ##(p<0.01) and ###(p<0.001). The results were determined using one-way ANOVA 
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with Tukey’s post hoc test and confirmed by three independent experiment 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effects of VDR ligands on pro-inflammatory secretion from IL-1β-stimulated human 
white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) for 24 h. Further 
groups of cells were pre-treated with 1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or 
ZK191784 (10 nM and 1 μM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
1α,25(OH)2D3 (10 nM) or ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) for a 
further 24 h before supernatant collection. The release levels of pro-inflammatory factors (A) IL-6, 
(B) IL-8, (C) MCP-1 and (D) RANTES were measured by ELISA and normalized by total cell 
protein content. Data are means ± SEM for groups of 6. A significant difference to control was 
indicated by ***(p<0.001); to IL-1β by #(p<0.05), ##(p<0.01) and ###(p<0.001). The results were 
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determined using one-way ANOVA with Tukey’s post hoc test and confirmed by three 
independent experiments.
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Fig. 3. Effects of ZK159222 and ZK191784 on cytokine release from IL-1β-stimulated 
human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) for 24 h. Further 
groups of cells were pre-treated with ZK159222 (1 μM) or ZK191784 (1 μM) for 48 h, followed 
by treatments with IL-1β (0.5 ng/ml) and ZK159222 (1 μM) or ZK191784 (1 μM) for a further 24 
h before supernatant collection. (A) The cytokine release levels were screened by cytokine array. 
(B) The results are presented as pixel density relative to the reference controls of the arrays. 
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Fig. 4. Modifying effects of VDR ligands on inflammatory associated signaling molecules in 
IL-1β-stimulated human white preadipocytes.  
Preadipocytes were either cultured alone (control), or with IL-1β (0.5 ng/ml) for 24 h. Further 
groups of cells were pre-treated with ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 
μM) or 1α,25(OH)2D3 (10 nM) for 48 h, followed by treatments with IL-1β (0.5 ng/ml) and 
ZK159222 (10 nM and 1 μM) or ZK191784 (10 nM and 1 μM) or 1α,25(OH)2D3 (10 nM) for a 
further 24 h before cell collection. (A) The levels of relA, phosphorylated relA, methylated relA, 
eIF-2α and phosphorylated eIF-2α were measured by western blotting. The results were presented 
as fold changes of ratios of (B) phosphorylated relA to relA, (C) methylated relA to relA and (D) 
phosphorylated eIF-2α to eIF-2α to controls. Data are means ± SEM for groups of 6. A significant 
difference to control was indicated by ***(p<0.001); to IL-1β by #(p<0.05), ##(p<0.01) and 
###(p<0.001). The results were determined using one-way ANOVA with Tukey’s post hoc test and 
confirmed by three independent experiments. 
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